Novel Technologies

New Hemophilia Treatments: Subcutaneous Injection

Two subcutaneous therapies are currently being investigated.

MLOF is open to all people with hemophilia A and B.

More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.

The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.

Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.

An update on FVII gene therapy and more.

Updates on Daklinza, Technivie, and the ACE910 trial

There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval...

Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for...

Novel Technologies, Hemophilia A&B

A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused...

Update, November 2014: The St. Jude/UCL gene therapy trial now has data from all 10 participants, to be published in...

Novel Technologies, Hemophilia A&B

Five pilot sites have been approved and first patients enrolled